Biodel Inc. reported results of preclinical tests which demonstrated the potential of the company’s glucose-regulated or “smart” basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions. In an oral presentation today at the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, Nandini Kashyap, director of novel drug delivery at Biodel, described results of in vitro and in vivo studies with diabetic pigs which compared the use of BIOD620 to Lantus(R) (insulin glargine). BIOD620 is Biodel’s proprietary injectable formulation of insulin glargine that has been designed to alter its insulin release profile in response to changing glucose concentration.
Six fasted diabetic pigs received a subcutaneous injection of 0.25U/kg of BIOD620 or Lantus(R). Their blood glucose was monitored every 15 minutes. Six hours after receiving their initial injection, they were fed 500 grams of food as a glucose challenge. BIOD620 was able to reduce the elevated plasma glucose levels faster than the group receiving Lantus(R). Furthermore, post-meal hyperglycemia was reduced more rapidly in the BIOD620 group than in the control group.
Dr. Solomon Steiner, chief scientific officer of Biodel, commented: “We are excited about these results because they suggest we have developed a new form of basal insulin that adjusts automatically to changing glucose levels.”
